Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections.

We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Choroidal Neovascularization Choroid Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Uveal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Retina Support Services, Inc

Tulsa, Oklahoma, 74127, United States

About this study

We will assess the trend of intraocular pressure immediately following intravitreal injection of ranibizumab 0.5 mg (0.05 mL) by taking serial intraocular pressure readings every five minutes for thirty minutes after injection. This study is a prospective descriptive data collection consisting of measuring intraocular pressure immediately following intraocular injection, and at 5, 10, 15, 20, 25, and 30 minutes following injection of ranibizumab 0.5 mg.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or Female Patients >18 years of age
Patients will have documented choroidal neovascular membranes on fluorescein angiogram and/or optical coherence tomography
Requiring treatment or maintenance therapy for choroidal neovascular membrane
Able and willing to provide written informed consent

Exclusion criteria

History of arterial occlusive disease of the eye.
History of advanced glaucoma.

Sponsors and collaborators

Lead sponsor

Oklahoma State University Center for Health Sciences

Other

Registry information

Official study title

A Prospective Investigation of the Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Jan 4, 2007
Registry last updated: Jan 24, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed